Protagonist Therapeutics (PTGX) PT Trimmed to $42 at BMO Capital, But Sees Catalyst-Rich 2018

March 8, 2018 5:47 AM

BMO Capital analyst M. Ian Somaiya lowered his price target on Protagonist Therapeutics (NASDAQ: PTGX) to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found